Abeona Therapeutics Inc.

NASDAQ:ABEO

Biotechnology

Healthcare
$2.73 +1.06%

+$0.06 today

Market cap
$156.01M
Beta
1.35
P/E (TTM)
4.9
EPS (TTM)
$1.17
52W Low $4.00High $7.54

Volume 1.71M

Average 1.12M

ABEO Weighted Avg Shares (Diluted)

Average shares outstanding including dilutive securities, used to calculate diluted EPS.

Abeona Therapeutics Inc.NASDAQ: ABEO

Weighted Avg Shares (Diluted) · Q1 FY2026 · quarter ended Mar 2026

Weighted avg shares (diluted) grows, but more slowly than its trailing trend

Q1 FY2026 weighted avg shares (diluted) of 56.62M shares rose 13.7% year over year, behind the +28.1% change in trailing-twelve-month weighted avg shares (diluted). Sequentially, it fell 14.4% from the prior quarter. Over 3 fiscal years it compounded at +103.4% a year.

Context

  • Weighted avg shares (diluted) increased in 3 of the last 3 fiscal years.
  • FY2025 was the highest annual figure in the 4 fiscal years shown.

What to watch

Whether quarterly growth recovers from +13.7% toward the trailing-twelve-month pace of +28.1%.

Sources:Income StatementText generated from reported figures; not investment advice.

Latest quarterMar 2026
56.62M-14.4% QoQ
Last fiscal yearDec 2025
66.14M+61.1% YoY
LTMMar 2026
60.91M+28.1% YoY
Weighted Avg Shares (Diluted) past and forecast growth by horizon
Horizon Past Forecast Difference
Quarter+13.7%——
1 year+61.1%——
3-year CAGR+103.4%——
5-year CAGR——
10-year CAGR——

Weighted Avg Shares (Diluted) history

Shares · from the income statement

Latest · FY2025
66.14M USD
Year-over-year change
+61.1%
4-year CAGR
+102.4%

Weighted Avg Shares (Diluted) vs competitors

How ABEO compares with its peers on the latest reported figures

  • ABEO's LTM Mar 2026 weighted avg shares (diluted) of 60.91M shares is the 5th highest of the 10 companies compared; the peer median is 58.91M shares.
  • Its year-over-year change of +28.1% is the 5th highest of 10, against a peer median of +7.9%.
  • Over three fiscal years its annual growth of +103.4% compares with a peer median of +15.2%.
ABEO Competitors Peer median
Weighted Avg Shares (Diluted) for ABEO and competitors
Company Period LTM YoY 3-year CAGR
HUMAHumacyte, Inc.LTM Mar 2026167.44M +37.0%+15.3%
TNYATenaya Therapeutics, Inc.LTM Mar 2026158.02M +71.7%+50.6%
ELDNEledon Pharmaceuticals, Inc.LTM Mar 202685.54M +45.8%+78.9%
FHTXFoghorn Therapeutics Inc.LTM Mar 202664.63M +7.9%+14.8%
ABEOAbeona Therapeutics Inc.LTM Mar 202660.91M +28.1%+103.4%
VYGRVoyager Therapeutics, Inc.LTM Mar 202658.91M +1.6%+15.2%
PBYIPuma Biotechnology, Inc.LTM Mar 202650.86M +3.4%+4.1%
SGMTSagimet Biosciences Inc.LTM Mar 202632.39M +0.9%+13.4%
ARCTArcturus Therapeutics Holdings Inc.LTM Mar 202627.53M +1.8%+0.4%
ASMBAssembly Biosciences, Inc.LTM Mar 202610.86M +66.5%+40.6%
Peer median (excluding ABEO) 58.91M+7.9%+15.2%

Competitors are the stored peer set for ABEO. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Income Statement

USD
Metric
FY2021
Dec 2021
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Revenue3M1.41M3.5M05.82M
Cost of Revenue0450K1.61M2.91M1.53M
Gross Profit3M964K1.9M(2.91M)4.29M
Gross Margin100.0%68.2%54.1%—73.7%
Research & Development38.73M28.97M31.09M34.36M26.81M
Selling, General & Admin21.64M17.26M19M29.85M65.03M
Operating Expenses92.84M51.88M49.03M61.3M93.74M
Depreciation & Amortization4.46M4.58M3.2M2.91M3.56M
EBITDA(76.82M)(34.38M)(50.57M)(56.62M)78.59M
EBITDA Margin-2560.5%-2431.6%-1444.9%—1350.3%
Operating Income(89.84M)(50.92M)(47.14M)(64.21M)(89.45M)
Operating Margin-2994.5%-3600.8%-1346.7%—-1536.9%
Interest Income40K431K2.12M4.25M5.56M
Interest Expense3.66M736K418K4.21M3.74M
Other Income / Expenses4.9M11.22M(7.05M)477K160.73M
Income Before Tax(84.94M)(39.7M)(54.19M)(63.73M)71.28M
Pre-Tax Margin-2831.2%-2807.4%-1548.2%—1224.8%
Income Tax Expense0000100K
Net Income(84.94M)(39.7M)(54.19M)(63.73M)71.18M
Net Margin-2831.2%-2807.4%-1548.2%—1223.1%
EPS (Basic)(21.50)(5.53)(2.53)(1.55)1.34
EPS (Diluted)(21.50)(5.53)(2.53)(1.55)1.01
Weighted Avg Shares3.94M7.86M21.38M41.05M52.95M
Weighted Avg Shares (Diluted)3.94M7.86M21.38M41.05M66.14M

Abeona Therapeutics Inc.

NASDAQ:ABEO

Intrinsic Alpha fair value

Locked

Current Price

$2.73

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.